U.S. Markets closed
  • S&P 500

    3,785.38
    -33.45 (-0.88%)
     
  • Dow 30

    30,775.43
    -253.88 (-0.82%)
     
  • Nasdaq

    11,028.74
    -149.16 (-1.33%)
     
  • Russell 2000

    1,707.99
    -11.38 (-0.66%)
     
  • Crude Oil

    105.85
    -3.93 (-3.58%)
     
  • Gold

    1,808.20
    -9.30 (-0.51%)
     
  • Silver

    20.17
    -0.50 (-2.41%)
     
  • EUR/USD

    1.0487
    +0.0043 (+0.4090%)
     
  • 10-Yr Bond

    2.9720
    -0.1210 (-3.91%)
     
  • Vix

    28.71
    +0.55 (+1.95%)
     
  • GBP/USD

    1.2177
    +0.0055 (+0.4505%)
     
  • USD/JPY

    135.7590
    -0.7860 (-0.5756%)
     
  • BTC-USD

    18,869.08
    -1,283.70 (-6.37%)
     
  • CMC Crypto 200

    404.82
    -26.65 (-6.18%)
     
  • FTSE 100

    7,169.28
    -143.04 (-1.96%)
     
  • Nikkei 225

    26,393.04
    -411.56 (-1.54%)
     

Vanda Pharmaceuticals Announces Presentations at SLEEP 2022

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

WASHINGTON, May 31, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2022, to be held in Charlotte, North Carolina from June 4-8, 2022.

The following scientific posters will be presented:

June 7, 2022

Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics
Poster Session Presentation Time: 5:15 PM7:15 PM ET

Title: "Enrichment of RAI1 genetic aberrations associated with sleep disturbances in SMS, in Autism Spectrum Disorder"  
Poster Number: 007

Title: "A 10-week observational research study in individuals with delayed sleep-wake phase disorder (DSWPD) symptoms"
Poster Number: 028

Title: "A novel missense variant in Melanopsin associates with delayed sleep phenotype: whole-genome sequencing study"  
Poster Number: 285

For more information on SLEEP 2022, please refer to https://www.sleepmeeting.org/.

About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.

Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com

Elizabeth Van Every
Head of Corporate Affairs
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-presentations-at-sleep-2022-301558351.html

SOURCE Vanda Pharmaceuticals Inc.